137 related articles for article (PubMed ID: 12569288)
21. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
22. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
Bajetta E; Del Vecchio M; Vitali M; Martinetti A; Ferrari L; Queirolo P; Sertoli MR; Cainelli T; Cellerino R; Cascinelli N
Tumori; 2001; 87(4):219-22. PubMed ID: 11693798
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
Verschraegen CF; Legha SS; Hersh EM; Plager C; Papadopoulos N; Burgess MA
Eur J Cancer; 1993; 29A(5):708-11. PubMed ID: 8471328
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
Margolin KA; Liu PY; Unger JM; Fletcher WS; Flaherty LE; Urba WJ; Hersh EM; Hutchins LE; Sosman JA; Smith JW; Weiss GR; Sondak VK
J Cancer Res Clin Oncol; 1999; 125(5):292-6. PubMed ID: 10359134
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Carmo-Pereira J; Costa FO; Henriques E
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1435-9. PubMed ID: 3595669
[TBL] [Abstract][Full Text] [Related]
26. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
[TBL] [Abstract][Full Text] [Related]
27. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
28. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Lattanzi SC; Tosteson T; Chertoff J; Maurer LH; O'Donnell J; LeMarbre PJ; Mott L; DelPrete SA; Forcier RJ; Ernstoff MS
Melanoma Res; 1995 Oct; 5(5):365-9. PubMed ID: 8541728
[TBL] [Abstract][Full Text] [Related]
29. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
[TBL] [Abstract][Full Text] [Related]
31. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
[TBL] [Abstract][Full Text] [Related]
32. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Chiarion Sileni V; Nortilli R; Aversa SM; Paccagnella A; Medici M; Corti L; Favaretto AG; Cetto GL; Monfardini S
Melanoma Res; 2001 Apr; 11(2):189-96. PubMed ID: 11333130
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
Mulder NH; Sleijfer DT; de Vries EG; Schraffordt Koops H; Samson MJ; Willemse PH
J Cancer Res Clin Oncol; 1989; 115(1):93-5. PubMed ID: 2466036
[TBL] [Abstract][Full Text] [Related]
34. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma.
Feun LG; Savaraj N; Hurley J; Marini A; Lai S
Cancer; 2000 Feb; 88(3):584-8. PubMed ID: 10649251
[TBL] [Abstract][Full Text] [Related]
35. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
Young AM; Marsden J; Goodman A; Burton A; Dunn JA
Clin Oncol (R Coll Radiol); 2001; 13(6):458-65. PubMed ID: 11824887
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma.
Pectasides D; Alevizakos N; Bafaloukos D; Tzonou A; Asimakopoulos G; Varthalitis I; Dimitriadis M; Athanassiou A
Am J Clin Oncol; 1994 Feb; 17(1):55-9. PubMed ID: 8311008
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
38. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
[TBL] [Abstract][Full Text] [Related]
39. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
Verschraegen CF; Kleeberg UR; Mulder J; Rumke P; Truchetet F; Czarnetzki B; Rozencweig M; Thomas D; Suciu S
Cancer; 1988 Sep; 62(6):1061-5. PubMed ID: 3409184
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
Nathan FE; Berd D; Sato T; Mastrangelo MJ
Cancer; 2000 Jan; 88(1):79-87. PubMed ID: 10618609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
